Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$11.21 USD
+0.12 (1.08%)
Updated Aug 12, 2022 04:00 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Income Statements
Fiscal Year end for Teva Pharmaceutical Industries Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 | |
---|---|---|---|---|---|
Sales | 15,878 | 16,659 | 16,887 | 18,854 | 22,385 |
Cost Of Goods | 8,284 | 8,933 | 9,351 | 10,558 | 11,560 |
Gross Profit | 7,594 | 7,726 | 7,536 | 8,296 | 10,825 |
Selling & Adminstrative & Depr. & Amort Expenses | 5,879 | 6,669 | 7,980 | 9,933 | 28,309 |
Income After Depreciation & Amortization | 1,715 | 1,057 | -444 | -1,637 | -17,484 |
Non-Operating Income | -1,058 | -5,462 | -822 | -959 | -895 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 658 | -4,406 | -1,265 | -2,596 | -18,379 |
Income Taxes | 211 | -168 | -278 | -195 | -1,933 |
Minority Interest | 39 | -109 | -2 | -322 | -184 |
Investment Gains/Losses | 9 | 138 | -13 | -71 | -3 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 456 | -4,100 | -1,000 | -2,472 | -16,449 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 417 | -3,990 | -998 | -2,150 | -16,265 |
Depreciation Footnote | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 3,045 | 2,614 | 1,278 | 205 | -15,372 |
Depreciation & Amortization (Cash Flow) | 1,330 | 1,557 | 1,722 | 1,842 | 2,112 |
Income After Depreciation & Amortization | 1,715 | 1,057 | -444 | -1,637 | -17,484 |
Earnings Per Share Data | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Average Shares | 1,107.00 | 1,095.00 | 1,091.00 | 1,021.00 | 1,016.00 |
Diluted EPS Before Non-Recurring Items | 2.48 | 2.45 | 2.31 | 2.80 | 3.93 |
Diluted Net EPS (GAAP) | 0.38 | -3.64 | -0.91 | -2.35 | -16.26 |
Fiscal Year end for Teva Pharmaceutical Industries Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/22 | 3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | |
---|---|---|---|---|---|
Sales | 3,786.00 | 3,661.00 | 4,099.00 | 3,887.00 | 3,910.00 |
Cost Of Goods | 1,992.00 | 1,921.00 | 2,050.00 | 2,093.00 | 2,037.00 |
Gross Profit | 1,794.00 | 1,740.00 | 2,049.00 | 1,794.00 | 1,873.00 |
SG&A, R&D, and Dept/Amort Expenses | 2,744.00 | 2,454.00 | 1,973.00 | 1,171.00 | 1,291.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -950.00 | -714.00 | 76.00 | 623.00 | 582.00 |
Non-Operating Income | -211.00 | -258.00 | -253.00 | -241.00 | -274.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1,160.00 | -971.00 | -176.00 | 382.00 | 308.00 |
Income Taxes | -900.00 | 2.00 | -25.00 | 76.00 | 98.00 |
Minority Interest | -27.00 | 3.00 | 7.00 | 11.00 | 14.00 |
Investment Gains/Losses | 0.00 | 21.00 | 0.00 | -5.00 | 11.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -260.00 | -952.00 | -151.00 | 301.00 | 221.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -232.00 | -955.00 | -158.00 | 291.00 | 207.00 |
Earnings Per Share Data | 6/30/22 | 3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 |
---|---|---|---|---|---|
Average Shares | 1,110.00 | 1,107.00 | 1,103.00 | 1,109.00 | 1,109.00 |
Diluted EPS Before Non-Recurring Items | 0.64 | 0.53 | 0.74 | 0.57 | 0.57 |
Diluted Net EPS (GAAP) | -0.21 | -0.86 | -0.14 | 0.26 | 0.19 |